Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key ...

Shares in GSK fell today on a 2% decline in vaccine sales in the third quarter, although demand for other medicines was strong and there are signs that the revamp of the business under new management ...

There is a moment, somewhere in a pharma content workflow, when a draft stops being a draft and becomes an action – sent, routed, acted on. Agentic AI is pulling that moment earlier and earlier, ...

Switzerland's Ferring Pharma has reached an agreement to buy US women's health startup Gameto for up to $1.38 billion, ...

Sweden's Egetis Therapeutics has launched the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency in the US, Emcitate, with a list price of around $950,000 per ...

While Anthropic has not disclosed the number of shares to be released, their price range, or a date for the listing, ...

The Novartis Pavillon in Park South of the Novartis Campus in Basel, Switzerland. Novartis's third-quarter results included a ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

Novo filed its lawsuit in the summer, accusing Lilly of a "nationwide pattern of deceptive advertising" for its obesity therapy Zepbound and type 2 diabetes (T2D) drug Mounjaro, both based on the dual ...

UK biotech sector has shrugged off a difficult economic environment with a 44% increase in venture capital investment in the ...